Tau plays a key role in Alzheimer’s disease (AD) pathophysiology, and accumulating
evidence suggests that lowering tau may reduce this pathology. We sought to inhibit MAPT …

An increasing proportion of cognitive difficulties are recognized to have a functional cause,
the chief clinical indicator of which is internal inconsistency. When these symptoms are …

Background: current literature suggests that two-thirds of patients will have cognitive impairment
at 3 months post-stroke. Post-stroke cognitive impairment is associated with impaired …

Alzheimer’s disease (AD) accounts for 60%–70% of all dementia cases, and clinical diagnosis
at its early stage is extremely difficult. As several new drugs aiming to modify disease …

Alzheimer’s disease (AD) is the most common cause of dementia worldwide and is
characterised pathologically by the accumulation of amyloid beta and tau protein aggregates. …

Background Stroke is associated with the development of cognitive impairment and dementia.
We assessed the effect of intensive blood pressure (BP) and/or lipid lowering on cognitive …

Introduction or background Memory problems are a very common reason for presenting to
primary care. There is a need for better treatments for dementia. Increased government and …

Alzheimer's disease (AD) is the leading cause of dementia worldwide. Mitochondrial
abnormalities have been identified in many cell types in AD, with deficits preceding the …

Neurodegenerative diseases are a group of nervous system conditions characterised
pathologically by the abnormal deposition of protein throughout the brain and spinal cord. One …

Alzheimer’s disease (AD) is the leading form of dementia worldwide. AD disrupts neuronal
pathways and thus is commonly viewed as a network disorder. Many studies demonstrate the …